Errata - English

In Dissolution 〈711〉/Test 2/Acid stage: Change
Acid stage standard solution: (L/10) mg/mL of USP Pantoprazole Sodium RS from the Standard stock solution in Acid stage medium, where L is the label claim in mg/Tablet
to:
Acid stage standard solution: (L/10000) mg/mL of USP Pantoprazole Sodium RS from the Standard stock solution in Acid stage medium, where L is the label claim in mg/Tablet
AND
In Dissolution <711>/Test 2/Buffer stage: Change
Buffer stage standard solution: (L/1000) of USP Pantoprazole Sodium RS where L is the label claim in mg/Tablet
to:
Buffer stage standard solution: (L/1000) mg/mL of USP Pantoprazole Sodium RS from the Standard stock solution in Buffer stage medium, where L is the label claim in mg/Tablet

In Test 2/Analysis: Change
C_S = concentration of USP Norethindrone Acetate RS (mg/mL) or USP Ethinyl Estradiol RS (ug/mL) in the Standard solution
to:
C_S = concentration of USP Norethindrone Acetate RS (mg/mL) or USP Ethinyl Estradiol RS (µg/mL) in the Standard solution

In USP Econazole Related Compound B RS: Change
Econazole amine;
2-[(4-Chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethanamine.
C₁₅H₁₄Cl₃NO 330.64
to:
Econazole amine;
2-[(4-Chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethanamine nitrate.
C₁₅H₁₄Cl₃NO · HNO₃ 393.65

Change
Similarly, a specific gravity value of 0.8092 in column 1 corresponds to a solution that contains 95% alcohol by weight or 92.42% alcohol v/v.
to:
Similarly, a specific gravity value of 0.8092 in column 1 corresponds to a solution that contains 95% alcohol v/v or 92.42% alcohol by weight.

In USP Pyrantel Related Compound A RS: Change
(Z)-1-Methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine.
C₃₄H₃₀N₂O₆S 594.69
to:
(Z)-1-Methyl-2-[2-(2-thiophenyl)vinyl]-1,4,5,6-tetrahydropyrimidine 4,4’-methylenebis[3-hydroxy-2-naphthoate] (1:1).
C₁₁H₁₄N₂S · C₂₃H₁₆O₆ 594.68

Change
USP Eleutheroside B RS
β-D-Glucopyranoside, 4-(3-hydroxy-1-propenyl)-2,6-dimethoxyphenyl.
C₁₇H₂₄O₉ 372.37
USP Eleutheroside E RS
β-D-Glucopyranoside, (tetrahydro-1H,3H-furo(3,4-c)furan-1,4-diyl)bis(2,6-dimethoxy-4,1-phenylene)bis-.
C₃₄H₄₆O₁₈ 742.70
to:
USP Eleutheroside B RS
USP Eleutheroside E RS

In Test 1/Apparatus 2: Change
[Note—A suitable sinker is available from VanKel, www.chem.agilent.com, catalog number 12-3050. Proper placement of the Capsules is in the sinkers with the cap facing the fixed prong end.]
to:
[Note—A suitable sinker is available from www.agilent.com, catalog number 12-3050. Proper placement of the Capsules is in the sinkers with the cap facing the fixed prong end.]

In Analysis: Change
Result = {r_U/[r_S + (Σr_U/F)]} × (1/F) × 100
to:
Result = {r_U/[r_S + Σ(r_U/F)]} × (1/F) × 100

In USP Succinylmonocholine Chloride RS: Change
Ethanaminium, 2-(carboxy-1-oxopropoxy)-N,N,N-trimethyl-, chloride.
to:
Ethanaminium, 2-(3-carboxy-1-oxopropoxy)-N,N,N-trimethyl-, chloride;
Also known as 2-[(3-Carboxypropanoyl)oxy]-N,N,N-trimethylethan-1-aminium chloride.

In Medium: Change
Sodium phosphate buffer, pH of 6.0 (14.2 g/L of disodium hydrogen orthophosphate anhydrous in water, adjusted with dilute hydrochloric acid to a pH of 6.0)
to:
Sodium phosphate buffer, pH 6.0 (14.2 g/L of sodium phosphate, dibasic, anhydrous in water, adjusted with dilute hydrochloric acid to pH 6.0)
AND
In Solution A: Change
orthophosphoric acid
to:
phosphoric acid

Change
USP Ondansetron RS
USP Ondansetron Related Compound C RS
1,2,3,9-Tetrahydro-9-methyl-4H-carbazol-4-one.
USP Ondansetron Related Compound D RS
1,2,3,9-Tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one.
to:
USP Ondansetron RS
USP Ondansetron Related Compound A RS
3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride.
USP Ondansetron Related Compound C RS
9-Methyl-1,2,3,9-tetrahydro-4H-carbazol-4-one.
USP Ondansetron Related Compound D RS
9-Methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one.

In paragraph five: Change
Determination of Zeta Potential by Electrophoretic Light Scattering 〈432〉¹
to:
Determination of Zeta Potential by Electrophoretic Light Scattering 〈432〉
AND
In footnote 1: Change
This chapter will appear in a future Pharmacopeial Forum (PF) issue.
to:
This chapter appeared in issue 46(3) of the Pharmacopeial Forum (PF).

In Analysis: Change
Result = {[(V_S − V_B) × N × F]/W} × 100
to:
Result = {[(V_S − V_B) × M × F]/W} × 100
AND
Change
N = actual normality of the Titrant (mEq/mL)
F = equivalency factor, 320.2 mg/mEq
to:
M = actual molarity of the Titrant (mmol/mL)
F = equivalency factor, 320.26 mg/mmol

In Analysis: Change
To 2.0 mL of the Sample solution, add 5.0 mL of a 4-g/L solution of methylbenzothiazolone hydrazone hydrochloride to an 80% (v/v) solution of glacial acetic acid in water.
to:
To 2.0 mL of the Sample solution, add 5.0 mL of a 4-g/L solution of methylbenzothiazolone hydrazone hydrochloride in an 80% (v/v) solution of glacial acetic acid in water.

In USP Atorvastatin Related Compound C RS: Change
C₆₆H₆₆F₄N₄O₁₀
to:
C₆₆H₆₆CaF₄N₄O₁₀
AND
In USP Atorvastatin Related Compound E RS: Change
1155.38
to:
1155.36

In Vitamins B3 (as Niacinamide), B6, and Folic Acid, Method 1/System suitability: Change
[Note—The relative retention times for niacinamide, pyridoxine, and folic acid are about 1.0, 1.6, 2.0, and 3.0 respectively.]
to:
[Note—The relative retention times for niacinamide, pyridoxine, and folic acid are about 1.0, 2.0, and 3.0, respectively.]
AND
In Vitamins B1 (as Thiamine Ion) and B2 (as Riboflavin), Method 1; Vitamin C (as Ascorbic Acid), Vitamins B3 (as Niacinamide), B6 (as Pyridoxine), and Folic Acid, Method 2/Analysis: Change
Calculate the percentage of the labeled amount of vitamin B1 as thiamine ion (C₁₂H₁₇N₄OS⁺), vitamin B2 as riboflavin (C₁₇H₂₀N₄O₆), vitamin B3 as niacinamide (C₆H₆N₂O), vitamin B6 as pyridoxine (C₈H₁₁NO₃), and folic acid (C₁₉H₁₉N₇O₆), in the portion of Chewable Gels taken:
to:
Calculate the percentage of the labeled amount of vitamin C as ascorbic acid (C₆H₈O₆), vitamin B1 as thiamine ion (C₁₂H₁₇N₄OS⁺), vitamin B2 as riboflavin (C₁₇H₂₀N₄O₆), vitamin B3 as niacinamide (C₆H₆N₂O), vitamin B6 as pyridoxine (C₈H₁₁NO₃), and folic acid (C₁₉H₁₉N₇O₆), in the portion of Chewable Gels taken:
AND
In Vitamins B1 (as Thiamine Ion) and B2 (as Riboflavin), Method 1; Vitamin C (as Ascorbic Acid), Vitamins B3 (as Niacinamide), B6 (as Pyridoxine), and Folic Acid, Method 2/Acceptance criteria: Change
90.0%–150.0% of the labeled amounts of vitamin B3 as niacinamide, vitamin B6 as pyridoxine, riboflavin, and thiamine as thiamine ion (C₁₂H₁₇N₄OS⁺); and NLT 90.0% and NMT 245.0% of the labeled amount of folic acid
to:
90.0%–250.0% of the labeled amount of vitamin C as ascorbic acid; 90.0%–150.0% of the labeled amounts of vitamin B3 as niacinamide, vitamin B6 as pyridoxine, riboflavin, and thiamine as thiamine ion (C₁₂H₁₇N₄OS⁺); and NLT 90.0% and NMT 245.0% of the labeled amount of folic acid

In both variable definition lists in Analysis: Change
M_r1 = molecular weight of fentanyl citrate, 528.59
M_r2 = molecular weight of fentanyl, 336.47
to:
M_r1 = molecular weight of fentanyl citrate, 528.60
M_r2 = molecular weight of fentanyl, 336.48

In Overview: Change
The test is also sensitive to size accuracy at 15 μm, since small errors in size will translate into large errors in count at the midpoint of the PS distribution.
to:
The test is also sensitive to size accuracy at 15 μm, since small errors in size will translate into large errors in count at the midpoint of the particle size distribution.

Change
(±)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-l-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
to:
(±)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid